Table 2.
Univariate Analysis for Increased Tau Values
| Intercept | Coefficient | |||||
|---|---|---|---|---|---|---|
| Predictors/Independent Variables | Estimates | CI | P Value | Estimates | CI | P Value |
| Group (PXE) | 7.64 | 7.14–8.14 | <0.001 | 1.12 | 0.33–1.91 | 0.006 |
| Age at examination | 7.23 | 4.52–9.94 | <0.001 | 0.01 | −0.03 to 0.06 | 0.521 |
| Glaucoma diagnosis | 8.15 | 7.71–8.59 | <0.001 | −0.56 | −1.95 to 0.82 | 0.417 |
| Prior transient vision loss | 7.81 | 7.40–8.22 | <0.001 | 1.77 | 0.75–2.79 | 0.001 |
| PAD | 7.84 | 7.38–8.31 | <0.001 | 0.96 | 0.05–1.87 | 0.04 |
| Axial length | 2.71 | −6.46 to 11.88 | 0.555 | 0.23 | −0.16 to 0.62 | 0.243 |
| Angioid streak length | 7.7 | 7.21–8.19 | <0.001 | 0.12 | 0.03–0.22 | 0.01 |
| Number of previous anti-VEGF injection | 7.46 | 6.83–8.09 | <0.001 | 0.02 | 0.01–0.04 | 0.014 |
This table shows the univariate model with tau value as the dependent variable. Overall, tau values were significantly different in patients with prior transient vision loss, PAD, longer angioid streaks, and higher number of previous anti- VEGF injections.